Toggle Main Menu Toggle Search

Open Access padlockePrints

Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK

Lookup NU author(s): Dr Alex Battersby, Dr Ben Shillitoe, Dr Terence Flood, Professor Andrew Cant, Dr Catherine Stroud, Dr Andrew Gennery

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Patients with congenital agammaglobulinemia, characterized by a defect in B lymphocyte differentiation causing B alymphocytosis, require life-long IgG replacement. There is scant literature regarding the effectiveness of IgG treatment at preventing mucosal (particularly sinopulmonary tract) infection and whether current management adequately restores "normal" health and quality of life (QoL). We aimed to document infective episodes pre- and post-commencing IgG replacement, determine any change in lung function and structure and assess respiratory status and QoL in a cohort of patients treated in Newcastle.Clinical data were extracted from medical records of 15 patients identified from the immunology database, focusing on infective episodes, serial chest CT and spirometry results. Thirteen patients completed a selection of standardized and validated questionnaires assessing physical health, respiratory health and QoL.Pediatric patients on IgG therapy suffered fewer infections per patient year (0.74) than adults (2.13). 6/14 patients showed deteriorating respiratory status despite adequate therapy. Health questionnaires revealed a significant burden of respiratory disease on a patient's life.Clinical data showed patients with congenital agammaglobulinemia receiving immunoglobulin therapy retained a higher than average infection rate, most of which affected mucosal barriers. Most patients self-reported worse respiratory symptoms, a lower respiratory-related QoL and a lower general health QoL relative to a healthy population. Most participants had progressive structural lung damage and decreased lung function. These results suggest that current management is not entirely effective at preventing deterioration of respiratory health or restoring QoL.


Publication metadata

Author(s): Bryan BA, Battersby A, Shillitoe BMJ, Barge D, Bourne H, Flood T, Cant AJ, Stroud C, Gennery AR

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Immunology

Year: 2016

Volume: 36

Issue: 5

Pages: 472-479

Print publication date: 01/07/2016

Online publication date: 18/04/2016

Acceptance date: 05/04/2016

Date deposited: 28/07/2016

ISSN (print): 0271-9142

ISSN (electronic): 1573-2592

Publisher: Springer

URL: http://dx.doi.org/10.1007/s10875-016-0284-3

DOI: 10.1007/s10875-016-0284-3


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share